S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)

Biomerica Stock Price, News & Analysis (NASDAQ:BMRA)

$0.99
+0.05 (+5.32%)
(As of 12/5/2023 ET)
Compare
Today's Range
$0.91
▼
$1.05
50-Day Range
$0.71
▼
$1.04
52-Week Range
$0.70
▼
$4.00
Volume
89,827 shs
Average Volume
96,648 shs
Market Capitalization
$16.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

BMRA stock logo

About Biomerica Stock (NASDAQ:BMRA)

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

BMRA Stock Price History

BMRA Stock News Headlines

December 1, 2023 | americanbankingnews.com
Biomerica (NASDAQ:BMRA) Stock Crosses Below 200 Day Moving Average of $1.17
November 10, 2023 | tmcnet.com
Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16
December 5, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
November 8, 2023 | finance.yahoo.com
Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups
October 13, 2023 | markets.businessinsider.com
REPEAT - Biomerica Reports First Quarter 2024 Financial Results
October 13, 2023 | finanznachrichten.de
Biomerica, Inc.: Biomerica Reports First Quarter 2024 Financial Results
October 13, 2023 | markets.businessinsider.com
Biomerica Reports First Quarter 2024 Financial Results
September 26, 2023 | tmcnet.com
Dubai Government Grants Insurance Reimbursement for Biomerica's EZ Detect™ Colorectal Disease Screening Test
December 5, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
September 26, 2023 | finance.yahoo.com
Dubai Government Grants Insurance Reimbursement for Biomerica’s EZ Detect™ Colorectal Disease Screening Test
August 28, 2023 | tmcnet.com
Diagnostics Industry Leader Jack Kenny Joins Biomerica's Board of Directors
August 27, 2023 | finance.yahoo.com
Biomerica Full Year 2023 Earnings: US$0.50 loss per share (vs US$0.36 loss in FY 2022)
August 26, 2023 | finanznachrichten.de
Biomerica, Inc.: Biomerica Reports Fiscal 2023 Year End Results
August 25, 2023 | msn.com
Biomerica reports FY results
August 25, 2023 | finance.yahoo.com
Biomerica Reports Fiscal 2023 Year End Results
August 3, 2023 | it.tmcnet.com
CVS Health to Begin Nationwide In-Store Sales of Biomerica's EZ Detect™ Colorectal Disease Screening Test
June 21, 2023 | finance.yahoo.com
Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients
May 21, 2023 | seekingalpha.com
QRTEA, BIOC and AMTX among mid-day movers
May 18, 2023 | it.tmcnet.com
inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology
April 17, 2023 | finance.yahoo.com
Biomerica, Inc. (BMRA) Stock Historical Prices & Data - Yahoo Finance
April 17, 2023 | finance.yahoo.com
Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
April 15, 2023 | finanznachrichten.de
Biomerica, Inc.: Biomerica Reports Q3 Fiscal 2023 Results
April 14, 2023 | finance.yahoo.com
Biomerica Reports Q3 Fiscal 2023 Results
March 8, 2023 | finance.yahoo.com
Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed
March 7, 2023 | finance.yahoo.com
Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock
March 3, 2023 | finance.yahoo.com
Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock
March 2, 2023 | finance.yahoo.com
Biomerica Announces Proposed Underwritten Public Offering of Common Stock
See More Headlines
Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/12/2023
Today
12/05/2023
Next Earnings (Estimated)
1/12/2024
Fiscal Year End
5/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BMRA
CUSIP
N/A
CIK
73290
Web
www.biomerica.com
Phone
(949) 645-2111
Fax
949-553-1231
Employees
62
Year Founded
1971

Profitability

EPS (Most Recent Fiscal Year)
($0.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,140,000.00
Net Margins
-114.52%
Pretax Margin
-113.19%
Return on Equity
-69.43%
Return on Assets
-54.16%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.63
Quick Ratio
5.55

Sales & Book Value

Annual Sales
$5.34 million
Price / Sales
3.09
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.70 per share
Price / Book
1.40

Miscellaneous

Outstanding Shares
16,820,000
Free Float
14,551,000
Market Cap
$16.48 million
Optionable
Not Optionable
Beta
-0.64

Social Links

10 Best Stocks to Own in 2024 Cover
10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Zackary S. Irani (Age 57)
    Chairman & CEO
    Comp: $141.25k
  • Mr. Allen C. Barbieri (Age 65)
    Executive Vice-Chairman of the Board & Corporate Secretary
    Comp: $126.25k
  • Mr. Gary Lu CPA (Age 42)
    Principal Accounting Officer & CFO
    Comp: $260k
  • Ms. Lucy Liu Ph.D.
    Director of Manufacturing & Technical Operations
  • Hans Boehringer
    Senior Vice President of POC Research & Development
  • Mr. Robert W. Carlson
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions














BMRA Stock Analysis - Frequently Asked Questions

How have BMRA shares performed in 2023?

Biomerica's stock was trading at $3.35 on January 1st, 2023. Since then, BMRA stock has decreased by 70.7% and is now trading at $0.98.
View the best growth stocks for 2023 here.

Are investors shorting Biomerica?

Biomerica saw a decrease in short interest in November. As of November 15th, there was short interest totaling 360,100 shares, a decrease of 13.0% from the October 31st total of 414,100 shares. Based on an average trading volume of 53,600 shares, the short-interest ratio is currently 6.7 days.
View Biomerica's Short Interest.

When is Biomerica's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, January 12th 2024.
View our BMRA earnings forecast.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) issued its quarterly earnings data on Thursday, October, 12th. The company reported ($0.07) earnings per share (EPS) for the quarter. The firm had revenue of $1.71 million for the quarter. Biomerica had a negative trailing twelve-month return on equity of 69.43% and a negative net margin of 114.52%.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

Who are Biomerica's major shareholders?

Biomerica's stock is owned by a variety of retail and institutional investors. Top institutional investors include Potomac Capital Management Inc. (1.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allen Barbieri, Catherine Coste and Zackary S Irani.
View institutional ownership trends.

How do I buy shares of Biomerica?

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BMRA) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -